You are here
- Home
- Last 30 days trials
A Phase II, Multicenter, Open-Label, Dose-Escalation Study to Evaluate Safety and Tolerability of IV or SC Dose of MEDI-545, a Fully Human Monoclonal Antibody Directed Against Interferon Alpha Subtypes, in Japanese Patients Who Have Systemic Lupus Erythematosus (SLE
- Disease
- systemic lupus erthematosus
- Drug Name
- AstraZeneca Respiratory and Inflammation Development Drugs
- Generic Name
- medi-545
- Sponsor
- AstraZeneca
- Drug Status
- In Development
- Phase
- II
- Start Date
- Nov 25, 2009
- Study Name
- D2800C00001
- Study Id
- D2800C00001
- Recruiting Status
- Open
- Protocol Status
- Not Available
- Report Status
- Not Available
